Small intestinal bacterial overgrowth syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Small intestinal bacterial overgrowth syndrome
ICD-10	K63
ICD-9	579.9
DiseasesDB	29209
MedlinePlus	000222
eMedicine	med/198

Synonyms and keywords:SIBO; small bowel bacterial overgrowth.

WikiDoc Resources for Small intestinal bacterial overgrowth syndrome
Articles
Most recent articles on Small intestinal bacterial overgrowth syndrome Most cited articles on Small intestinal bacterial overgrowth syndrome Review articles on Small intestinal bacterial overgrowth syndrome Articles on Small intestinal bacterial overgrowth syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Small intestinal bacterial overgrowth syndrome Images of Small intestinal bacterial overgrowth syndrome Photos of Small intestinal bacterial overgrowth syndrome Podcasts & MP3s on Small intestinal bacterial overgrowth syndrome Videos on Small intestinal bacterial overgrowth syndrome
Evidence Based Medicine
Cochrane Collaboration on Small intestinal bacterial overgrowth syndrome Bandolier on Small intestinal bacterial overgrowth syndrome TRIP on Small intestinal bacterial overgrowth syndrome
Clinical Trials
Ongoing Trials on Small intestinal bacterial overgrowth syndrome at Clinical Trials.gov Trial results on Small intestinal bacterial overgrowth syndrome Clinical Trials on Small intestinal bacterial overgrowth syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Small intestinal bacterial overgrowth syndrome NICE Guidance on Small intestinal bacterial overgrowth syndrome NHS PRODIGY Guidance FDA on Small intestinal bacterial overgrowth syndrome CDC on Small intestinal bacterial overgrowth syndrome
Books
Books on Small intestinal bacterial overgrowth syndrome
News
Small intestinal bacterial overgrowth syndrome in the news Be alerted to news on Small intestinal bacterial overgrowth syndrome News trends on Small intestinal bacterial overgrowth syndrome
Commentary
Blogs on Small intestinal bacterial overgrowth syndrome
Definitions
Definitions of Small intestinal bacterial overgrowth syndrome
Patient Resources / Community
Patient resources on Small intestinal bacterial overgrowth syndrome Discussion groups on Small intestinal bacterial overgrowth syndrome Patient Handouts on Small intestinal bacterial overgrowth syndrome Directions to Hospitals Treating Small intestinal bacterial overgrowth syndrome Risk calculators and risk factors for Small intestinal bacterial overgrowth syndrome
Healthcare Provider Resources
Symptoms of Small intestinal bacterial overgrowth syndrome Causes & Risk Factors for Small intestinal bacterial overgrowth syndrome Diagnostic studies for Small intestinal bacterial overgrowth syndrome Treatment of Small intestinal bacterial overgrowth syndrome
Continuing Medical Education (CME)
CME Programs on Small intestinal bacterial overgrowth syndrome
International
Small intestinal bacterial overgrowth syndrome en Espanol Small intestinal bacterial overgrowth syndrome en Francais
Business
Small intestinal bacterial overgrowth syndrome in the Marketplace Patents on Small intestinal bacterial overgrowth syndrome
Experimental / Informatics
List of terms related to Small intestinal bacterial overgrowth syndrome

Overview

Small intestinal bacterial overgrowth (SIBO) was first discovered by Barber and Hummel in 1939. There is no established system for the classification of small intestinal bacterial overgrowth (SIBO).The pathogenesis of small intestinal bacterial overgrowth (SIBO) is characterized by an increased microbial load in the small intestine. Disruption of protective homeostatic mechanisms can increase the risk of SIBO. Bacterial colonization causes an inflammatory response in the intestinal mucosa. Damage to the intestinal mucosa leads to malabsorption of bile acids, carbohydrates, proteins and vitamins resulting in symptoms of diarrhea and weight loss. On gross pathology, mucosal edema, loss of normal vascular pattern, patchy erythema, friability and ulceration of the small intestinal wall is associated with small intestinal bacterial overgrowth (SIBO). On microscopic histopathological analysis small intestine and colon are normal in most patients with SIBO. Findings include blunting of the intestinal villi, thinning of the mucosa and crypts, increased intraepithelial lymphocytes. Small intestinal bacterial overgrowth (SIBO) must be differentiated from other diseases that cause chronic diarrhea. Small intestinal bacterial overgrowth is more commonly observed among elderly patients. Small intestinal bacterial overgrowth (SIBO) affects men and women equally.There is no racial predilection for small intestinal bacterial overgrowth (SIBO). Early clinical features include bloating, flatulence, abdominal pain. If left untreated, patients with small intestinal bacterial overgrowth (SIBO) may progress to develop diarrhea, dyspepsia and weight loss. Prognosis is generally good and associated with frequent relapses and symptom-free periods. The diagnosis of small intestinal bacterial overgrowth (SIBO) is made when at least one of the following diagnostic criteria are met: a positive carbohydrate breath test or bacterial concentration of >103 units/mL in a jejunal aspirate culture. Physical examination may be remarkable for distended abdomen with positive succussion splash as a result of distended bowel loops and peripheral edema due to malabsorption. Small intestinal bacterial obstruction(SIBO) may also be diagnosed using breath tests. The mainstay of therapy for small intestinal bacterial overgrowth (SIBO) is antibiotic therapy. Surgical approach can only be performed for patients with strictures, fistulae, and diverticula or any other structural abnormality resulting in obstruction and resultant bacterial overgrowth. Effective measures for the prevention of small bowel bacterial overgrowth syndrome include avoiding medications like narcotics and benzodiazepines that decrease intestinal motility and avoid achlorhydria in high-risk patients. Consider antibiotic prophylaxis for patients with four or more episodes of recurrent small bowel bacterial overgrowth syndrome within one year.

Historical Perspective

• Small intestinal bacterial overgrowth (SIBO) was first discovered by Barber and Hummel in 1939.
• In 2000, Pimentel et all at Cedars-Sinai Medical Center first identified that SIBO was present in 78% of patients with irritable bowel syndrome (IBS), and that treatment with antibiotics improved symptoms.
• In May 2015, U.S. Food and Drug Administration (FDA) approved rifaximin to treat SIBO.

Classification

• There is no established system for the classification of small intestinal bacterial overgrowth (SIBO).

Pathophysiology

• The pathogenesis of small intestinal bacterial overgrowth (SIBO) is characterized by an increased microbial load in the small intestine.
• A healthy individual has less than 103 organisms/mL in the upper small intestine and the majority of these organisms are gram-positive bacteria.
• Human body's homeostatic mechanisms that protect against excessive small intestinal colonization by bacteria include :
  • Gastric acid and bile eradicate micro-organisms before they leave the stomach.
  • Migrating motor complex clears the excess bacteria of upper intestine.
  • Intestinal mucosa serves as a protective layer for the gut wall.
  • Normal intestinal flora (eg, Lactobacillus) maintains a low pH that prevents bacterial overgrowth.
  • Physical barrier of the ileocecal valve that prevents retrograde translocation of bacteria from colon to the small intestine.
• Disruption of these protective homeostatic mechanisms can increase the risk of SIBO.
• Bacterial colonization causes an inflammatory response in the intestinal mucosa.
• Damage to the intestinal mucosa leads to malabsorption of bile acids, carbohydrates, proteins, and vitamins resulting in symptoms of diarrhea and weight loss.
• On gross pathology, mucosal edema, loss of normal vascular pattern, patchy erythema, friability and ulceration of the small intestinal wall is associated with small intestinal bacterial overgrowth (SIBO).
• On microscopic histopathological analysis small intestine and colon is normal in most patients with SIBO. However, in some patients, findings may include:
  • Blunting of the intestinal villi
  • Thinning of the mucosa and crypts
  • Increased intraepithelial lymphocytes

Causes

• Small intestinal bacterial overgrowth (SIBO) may be caused by disruption of the protective homeostatic mechanisms that control enteric bacteria population.
• Causes of small intestinal bacterial overgrowth (SIBO) include:
  • Irregular small intestinal motility:
    • Diabetic autonomic neuropathy
    • Scleroderma
    • Pseudo-obstruction
    • Amyloidosis
    • Neurological diseases (eg, myotonic dystrophy, Parkinson disease)
    • Radiation enteritis
    • Crohn disease
    • Hypothyroidism
  • Blind pouches in the gastrointestinal tract:
    • Side-to-side or end-to-side anastomoses
    • Duodenal or jejunal diverticula
    • Segmental dilatation of the ileum
    • Blind loop syndrome
    • Biliopancreatic diversion
    • Chagasic megacolon
  • Fistula:
    • Gastrocolic fistulae
    • Jejunal-colic fistulae
  • Partial Obstruction:
    • Strictures
    • Adhesions
    • Abdominal masses
    • Leiomyosarcoma
  • Decreased gastric acid secretion:
    • Achlorhydria
    • Vagotomy
    • Long-term proton pump inhibitor therapy

Differentiating Small Intestinal Bacterial Overgrowth from other Diseases

• Small intestinal bacterial overgrowth (SIBO) must be differentiated from other diseases that cause chronic diarrhea. For differential diagnosis of chronic diarrhoea, click here.

Epidemiology and Demographics

Age

• Small intestinal bacterial overgrowth is more commonly observed among elderly patients.

Gender

• Small intestinal bacterial overgrowth (SIBO) affects men and women equally.

Race

• There is no racial predilection for small intestinal bacterial overgrowth (SIBO).

Risk Factors

• Common risk factors in the development of small intestinal bacterial overgrowth (SIBO) are :
  • Intestinal tract surgery
  • Irritable bowel syndrome
  • Liver cirrhosis
  • Celiac disease
  • Immune deficiency (eg, AIDS, IgA deficiency, severe malnutrition)
  • Short bowel syndrome
  • End-stage renal disease
  • Gastrojejunal anastomosis
  • Antral resection
  • Pancreatic exocrine insufficiency

Natural History, Complications and Prognosis

• Early clinical features include bloating, flatulence, abdominal pain.
• If left untreated, patients with small intestinal bacterial overgrowth (SIBO) may progress to develop diarrhea, dyspepsia and weight loss.
• Common complications of small intestinal bacterial overgrowth (SIBO) include:
  • Iron deficiency resulting in microcytic anemia
  • Vitamin B-12 or folate deficiency resulting in macrocytic anemia
  • Vitamin B-12 deficiency associated polyneuropathy
  • Steatorrhea
  • Hypocalcemia
  • Vitamin A deficiency resulting in night blindness
  • Selenium deficiency causing dermatitis
  • Rosacea
  • Cachexia as a result of protein-energy malnutrition
• Prognosis is generally good and associated with frequent relapses and symptom-free periods.

Diagnosis

Diagnostic Criteria

• The diagnosis of small intestinal bacterial overgrowth (SIBO) is made when at least one of the following diagnostic criteria are met:

• A positive carbohydrate breath test
• Bacterial concentration of >103 units/mL in a jejunal aspirate culture

Symptoms

• Symptoms of small intestinal bacterial overdose (SIBO) may include the following:

• Bloating
• Flatulence
• Abdominal discomfort
• Chronic watery diarrhea
• Weight loss

Physical Examination

• Patients with small intestinal bacterial overgrowth (SIBO) usually appear normal.
• Physical examination may be remarkable for:

• Distended abdomen with positive succussion splash as a result of distended bowel loops
• Peripheral edema due to malabsorption

Laboratory Findings

• A positive carbohydrate breath test is diagnostic of small intestinal bacterial overgrowth (SIBO).
• An elevated concentration of bacterial colony forming units >103/mL in jejunal aspirate culture is diagnostic of small intestinal bacterial overgrowth (SIBO).
• Other laboratory findings consistent with the diagnosis of small intestinal bacterial overgrowth (SIBO) include:
  • Macrocytic anemia
  • B12 deficiency
  • Presence of fecal fat on stool examination.
  • Low levels of thiamine and niacin
  • Elevated serum folate and vitamin K levels

Imaging Findings

• The CT abdomen or MRI may demonstrate associated strictures, malrotation, fistulae.
• Small intestinal bacterial overgrowth can result in small bowel obstruction that presents as small bowel feces sign on abdominal CT.
• Small bowel feces sign is the presence of particulate feculent material mingled with gas bubbles in the lumen of the small intestine, it is believed to be the result of delayed intestinal transit.

Small bowel faeces signCase courtesy of Dr Ian Bickle, <a href="https://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="https://radiopaedia.org/cases/29769">rID: 29769</a>

Other Diagnostic Studies

Breath Tests

• Small intestinal bacterial obstruction (SIBO) may also be diagnosed using breath tests.
• Breath tests have the advantage of being easy to perform, noninvasive, and inexpensive. Breath tests are based on the principle that carbohydrates are metabolized by bacteria in the gut to produce hydrogen or methane that is absorbed and excreted in breath.
• The findings on carbohydrate breath test diagnostic of small intestinal bacterial obstruction (SIBO) include:
  • An increase in hydrogen by ≥20 ppm above baseline within 90 minutes.
  • A methane level ≥10 ppm regardless of the time during the breath test.

Treatment

Medical Therapy

• The mainstay of therapy for small intestinal bacterial overgrowth (SIBO) is antibiotic therapy.
• Antibiotics acts by eliminating the bacterial overgrowth.
• Rifaximin is the antibiotic of choice for the treatment of small intestinal bacterial overgrowth (SIBO).
  • Preferred regimen: Rifaximin 550 mg PO q8h for 14 days.
• Response to antibiotics can be assessed by the symptomatic improvement. In case of recurrent symptoms, the antibiotic dose is repeated.

Surgery

• Surgical approach can only be performed for patients with strictures, fistulae, and diverticula or any other structural abnormality resulting in obstruction and resultant bacterial overgrowth.

Prevention

• Effective measures for the prevention of small bowel bacterial overgrowth syndrome include:
  • Avoiding medications like narcotics and benzodiazepines that decrease intestinal motility.
  • Avoid achlorhydria in high-risk patients.
  • Consider antibiotic prophylaxis for patients with four or more episodes of recurrent small bowel bacterial overgrowth syndrome within one year.

External links

• IBS and small intestinal bacterial overgrowth (SIBO)

Template:WikiDoc Sources